{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:59:16Z","timestamp":1784696356030,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s12288-023-01673-y","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T13:02:36Z","timestamp":1685970156000},"page":"52-60","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lower Levels of TET2 Gene Expression, with a Higher Level of TET2 Promoter Methylation in Patients with AML; Evidence for the Role of Aberrant Methylation in AML Pathogenesis"],"prefix":"10.1007","volume":"40","author":[{"given":"Bahare","family":"Ghasemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Zaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahere","family":"Tabatabaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Kiani-Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5098-7240","authenticated-orcid":false,"given":"Ahmad","family":"Kazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"issue":"8","key":"1673_CR1","doi-asserted-by":"publisher","first-page":"984","DOI":"10.6004\/jnccn.2012.0103","volume":"10","author":"MR O'Donnell","year":"2012","unstructured":"O\u2019Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E et al (2012) Acute myeloid leukemia. J Natl Compr Canc Netw 10(8):984\u20131021","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"1673_CR2","doi-asserted-by":"publisher","first-page":"926","DOI":"10.6004\/jnccn.2017.0116","volume":"15","author":"MR O'Donnell","year":"2017","unstructured":"O\u2019Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA et al (2017) Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15(7):926\u2013957","journal-title":"J Natl Compr Canc Netw"},{"key":"1673_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/ijlh.12367","volume":"37","author":"R Ohgami","year":"2015","unstructured":"Ohgami R, Arber D (2015) The diagnostic and clinical impact of genetics and epigenetics in acute myeloid leukemia. Int J Lab Hematol 37:122\u2013132","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"1673_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-017-1281-x","volume":"15","author":"SH Lim","year":"2017","unstructured":"Lim SH, Dubielecka PM, Raghunathan VM (2017) Molecular targeting in acute myeloid leukemia. J Transl Med 15(1):1\u201313","journal-title":"J Transl Med"},{"issue":"1","key":"1673_CR5","first-page":"42","volume":"127","author":"BJ Wouters","year":"2016","unstructured":"Wouters BJ, Delwel R (2016) Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood J Am Soc Hematol 127(1):42\u201352","journal-title":"Blood J Am Soc Hematol"},{"key":"1673_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/103175","volume":"2014","author":"EC O\u2019Brien","year":"2014","unstructured":"O\u2019Brien EC, Prideaux S, Chevassut T (2014) The epigenetic landscape of acute myeloid leukemia. Adv Hematol 2014:1\u201315. https:\/\/doi.org\/10.1155\/2014\/103175","journal-title":"Adv Hematol"},{"issue":"8","key":"1673_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.exphem.2015.05.009","volume":"43","author":"A Eriksson","year":"2015","unstructured":"Eriksson A, Lennartsson A, Lehmann S (2015) Epigenetic aberrations in acute myeloid leukemia: early key events during leukemogenesis. Exp Hematol 43(8):609\u2013624","journal-title":"Exp Hematol"},{"issue":"2","key":"1673_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000452091","volume":"92","author":"V Hale","year":"2017","unstructured":"Hale V, Hale GA, Brown PA, Amankwah EK (2017) A review of DNA methylation and microRNA expression in recurrent pediatric acute leukemia. Oncology 92(2):61\u201367","journal-title":"Oncology"},{"issue":"2","key":"1673_CR9","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.3892\/mmr.2016.5387","volume":"14","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Jiang Q, Kong X, Yang L, Hu W, Lv C et al (2016) Methylation status of the promoter region of the human frizzled 9 genes in acute myeloid leukemia. Mol Med Rep 14(2):1339\u20131344","journal-title":"Mol Med Rep"},{"issue":"10","key":"1673_CR10","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.tig.2014.07.005","volume":"30","author":"Y Huang","year":"2014","unstructured":"Huang Y, Rao A (2014) Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet 30(10):464\u2013474","journal-title":"Trends Genet"},{"issue":"7","key":"1673_CR11","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/ng.391","volume":"41","author":"S Langemeijer","year":"2009","unstructured":"Langemeijer S, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al (2009) Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41(7):838\u2013842","journal-title":"Nat Genet"},{"issue":"10","key":"1673_CR12","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1136\/jcp.2010.080218","volume":"63","author":"C Chim","year":"2010","unstructured":"Chim C, Wan T, Fung T, Wong K (2010) Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms. J Clin Pathol 63(10):942\u2013946","journal-title":"J Clin Pathol"},{"key":"1673_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3389\/fcell.2018.00022","volume":"6","author":"P Melamed","year":"2018","unstructured":"Melamed P, Yosefzon Y, David C, Tsukerman A, Pnueli L (2018) Tet enzymes, variants, and differential effects on function. Front Cell Dev Biol 6:22","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1673_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-016-0298-y","volume":"8","author":"M Van Damme","year":"2016","unstructured":"Van Damme M, Crompot E, Meuleman N, Maerevoet M, Mineur P, Bron D et al (2016) Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance. Clin Epigenetics 8(1):1\u201311","journal-title":"Clin Epigenetics"},{"issue":"11","key":"1673_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.14348\/molcells.2015.0294","volume":"38","author":"J-A Han","year":"2015","unstructured":"Han J-A, An J, Ko M (2015) Functions of TET proteins in hematopoietic transformation. Mol Cells 38(11):925","journal-title":"Mol Cells"},{"issue":"8","key":"1673_CR16","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00432-014-1901-2","volume":"141","author":"AA Raw\u0142uszko-Wieczorek","year":"2015","unstructured":"Raw\u0142uszko-Wieczorek AA, Siera A, Horbacka K, Horst N, Krokowicz P, Jagodzi\u0144ski PP (2015) Clinical significance of DNA methylation mRNA levels of TET family members in colorectal cancer. J Canc Res Clin Oncol 141(8):1379\u20131392. https:\/\/doi.org\/10.1007\/s00432-014-1901-2","journal-title":"J Canc Res Clin Oncol"},{"issue":"5","key":"1673_CR17","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/s41375-019-0675-6","volume":"34","author":"N Duployez","year":"2020","unstructured":"Duployez N, Goursaud L, Fenwarth L, Bories C, Marceau-Renaut A, Boyer T et al (2020) Familial myeloid malignancies with germline TET2 mutation. Leukemia 34(5):1450\u20131453","journal-title":"Leukemia"},{"issue":"1","key":"1673_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/imr.12246","volume":"263","author":"BA Woods","year":"2015","unstructured":"Woods BA, Levine RL (2015) The role of mutations in epigenetic regulators in myeloid malignancies. Immunol Rev 263(1):22\u201335","journal-title":"Immunol Rev"},{"key":"1673_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3389\/fonc.2019.00210","volume":"9","author":"Y Feng","year":"2019","unstructured":"Feng Y, Li X, Cassady K, Zou Z, Zhang X (2019) TET2 function in hematopoietic malignancies, immune regulation, and DNA repair. Front Oncol 9:210","journal-title":"Front Oncol"},{"issue":"3","key":"1673_CR20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/leu.2013.337","volume":"28","author":"E Solary","year":"2014","unstructured":"Solary E, Bernard O, Tefferi A, Fuks F, Vainchenker W (2014) The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 28(3):485\u2013496","journal-title":"Leukemia"},{"issue":"6","key":"1673_CR21","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/iub.1389","volume":"67","author":"F Pan","year":"2015","unstructured":"Pan F, Weeks O, Yang FC, Xu M (2015) The TET2 interactors and their links to hematological malignancies. IUBMB Life 67(6):438\u2013445","journal-title":"IUBMB Life"},{"issue":"24","key":"1673_CR22","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.4161\/cc.8.24.10239","volume":"8","author":"SM Langemeijer","year":"2009","unstructured":"Langemeijer SM, Aslanyan MG, Jansen JH (2009) TET proteins in malignant hematopoiesis. Cell Cycle 8(24):4044\u20134048","journal-title":"Cell Cycle"},{"issue":"10","key":"1673_CR23","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1136\/jclinpath-2011-200133","volume":"64","author":"Y-H Kim","year":"2011","unstructured":"Kim Y-H, Pierscianek D, Mittelbronn M, Vital A, Mariani L, Hasselblatt M et al (2011) TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1\/2 mutations. J Clin Pathol 64(10):850\u2013852","journal-title":"J Clin Pathol"},{"issue":"12","key":"1673_CR24","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1038\/nprot.2008.191","volume":"3","author":"TK Wojdacz","year":"2008","unstructured":"Wojdacz TK, Dobrovic A, Hansen LL (2008) Methylation-sensitive high-resolution melting. Nat Protoc 3(12):1903\u20131908","journal-title":"Nat Protoc"},{"issue":"10","key":"1673_CR25","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.leukres.2015.07.005","volume":"39","author":"DF Coutinho","year":"2015","unstructured":"Coutinho DF, Monte-M\u00f3r BC, Vianna DT, Rouxinol ST, Batalha ABW, Bueno APS et al (2015) TET2 expression level and 5-hydroxymethylcytosine are decreased in refractory cytopenia of childhood. Leuk Res 39(10):1103\u20131108","journal-title":"Leuk Res"},{"issue":"1","key":"1673_CR26","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.4081\/hr.2014.5333","volume":"6","author":"E Musialik","year":"2014","unstructured":"Musialik E, Bujko M, Wypych A, Matysiak M, Siedlecki J (2014) TET2 promoter DNA methylation and expression analysis in pediatric B-cell acute lymphoblastic leukemia. Hematol Rep 6(1):5333. https:\/\/doi.org\/10.4081\/hr.2014.5333","journal-title":"Hematol Rep"},{"issue":"4","key":"1673_CR27","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.beha.2010.09.017","volume":"23","author":"AM Melnick","year":"2010","unstructured":"Melnick AM (2010) Epigenetics in AML. Best Pract Res Clin Haematol 23(4):463\u2013468","journal-title":"Best Pract Res Clin Haematol"},{"issue":"11","key":"1673_CR28","doi-asserted-by":"publisher","first-page":"18337","DOI":"10.18632\/oncotarget.15440","volume":"8","author":"H Yao","year":"2017","unstructured":"Yao H, Duan M, Lin L, Wu C, Fu X, Wang H et al (2017) TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population. Oncotarget 8(11):18337","journal-title":"Oncotarget"},{"issue":"1","key":"1673_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3233\/CBM-150543","volume":"16","author":"J Yang","year":"2016","unstructured":"Yang J, Xiao X, Li R, Li Z, Deng M, Zhang G (2016) Hypermethylation of CpG sites at the promoter region is associated with deregulation of mitochondrial ATPsyn-\u03b2 and chemoresistance in acute myeloid leukemia. Cancer Biomark 16(1):81\u201388","journal-title":"Cancer Biomark"},{"key":"1673_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/5472893","volume":"2017","author":"GM Dexheimer","year":"2017","unstructured":"Dexheimer GM, Alves J, Reckziegel L, Lazzaretti G, Abujamra AL (2017) DNA methylation events as markers for diagnosis and management of acute myeloid leukemia and myelodysplastic syndrome. Dis Mark 2017:1\u201314. https:\/\/doi.org\/10.1155\/2017\/5472893","journal-title":"Dis Mark"},{"issue":"7","key":"1673_CR31","first-page":"1110","volume":"124","author":"LI Kroeze","year":"2014","unstructured":"Kroeze LI, Aslanyan MG, van Rooij A, Koorenhof-Scheele TN, Massop M, Carell T et al (2014) Characterization of acute myeloid leukemia based on levels of global hydroxymethylation. Blood J Am Soc Hematol 124(7):1110\u20131118","journal-title":"Blood J Am Soc Hematol"},{"issue":"7","key":"1673_CR32","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1101\/gad.276568.115","volume":"30","author":"KD Rasmussen","year":"2016","unstructured":"Rasmussen KD, Helin K (2016) Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev 30(7):733\u2013750","journal-title":"Genes Dev"},{"issue":"1","key":"1673_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/cas.14688","volume":"112","author":"H Kunimoto","year":"2021","unstructured":"Kunimoto H, Nakajima H (2021) TET2: A cornerstone in normal and malignant hematopoiesis. Cancer Sci 112(1):31\u201340","journal-title":"Cancer Sci"},{"issue":"9","key":"1673_CR34","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/cas.12484","volume":"105","author":"H Nakajima","year":"2014","unstructured":"Nakajima H, Kunimoto H (2014) TET2 as an epigenetic master regulator for normal and malignant hematopoiesis. Cancer Sci 105(9):1093\u20131099","journal-title":"Cancer Sci"},{"issue":"1","key":"1673_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13000-016-0476-4","volume":"11","author":"R Scopim-Ribeiro","year":"2016","unstructured":"Scopim-Ribeiro R, Machado-Neto JA, de Melo CP, Niemann FS, Lorand-Metze I, Costa FF et al (2016) Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms. Diagn Pathol 11(1):1\u20135","journal-title":"Diagn Pathol"},{"issue":"4","key":"1673_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4103\/1110-1067.170194","volume":"40","author":"NA Hamed","year":"2015","unstructured":"Hamed NA, El Halawani NA, Kassem HS, Ayad MW, Dammag EA (2015) TET2 expression in a cohort of Egyptian acute myeloid leukemia patients. Egypt J Haematol 40(4):159","journal-title":"Egypt J Haematol"},{"issue":"8","key":"1673_CR37","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1002\/jcp.26373","volume":"233","author":"TJ Zhang","year":"2018","unstructured":"Zhang TJ, Zhou JD, Yang DQ, Wang YX, Wen XM, Guo H et al (2018) TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia. J Cell Physiol 233(8):5838\u20135846","journal-title":"J Cell Physiol"},{"issue":"2","key":"1673_CR38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/neup.12615","volume":"40","author":"D Pierscianek","year":"2020","unstructured":"Pierscianek D, Teuber-Hanselmann S, Ahmadipour Y, DarkwahOppong M, Unteroberd\u00f6rster M, M\u00fcller O et al (2020) TET2 promotor methylation and TET2 protein expression in pediatric posterior fossa ependymoma. Neuropathology 40(2):138\u2013143","journal-title":"Neuropathology"},{"issue":"7","key":"1673_CR39","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1530\/ERC-17-0009","volume":"24","author":"E Barazeghi","year":"2017","unstructured":"Barazeghi E, Gill AJ, Sidhu S, Norl\u00e9n O, Dina R, Palazzo FF et al (2017) A role for TET2 in parathyroid carcinoma. Endocr Relat Canc 24(7):329\u2013338","journal-title":"Endocr Relat Canc"},{"issue":"40","key":"1673_CR40","doi-asserted-by":"publisher","first-page":"25922","DOI":"10.18632\/oncotarget.25406","volume":"9","author":"MG Garc\u00eda","year":"2018","unstructured":"Garc\u00eda MG, Carella A, Urdinguio RG, Bay\u00f3n GF, Lopez V, Tejedor JR, Sierra MI, Garc\u00eda-Tora\u00f1o E et al (2018) Epigenetic dysregulation of TET2 in human glioblastoma. Oncotarget 9(40):25922\u201325934. https:\/\/doi.org\/10.18632\/oncotarget.25406","journal-title":"Oncotarget"},{"issue":"1","key":"1673_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.stem.2013.06.003","volume":"13","author":"SJ Song","year":"2013","unstructured":"Song SJ, Ito K, Ala U, Kats L, Webster K, Sun SM et al (2013) The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 13(1):87\u2013101","journal-title":"Cell Stem Cell"},{"issue":"1","key":"1673_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-56847-4","volume":"10","author":"J Wang","year":"2020","unstructured":"Wang J, He N, Wang R, Tian T, Han F, Zhong C et al (2020) Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia. Sci Rep 10(1):1\u201311","journal-title":"Sci Rep"},{"issue":"8","key":"1673_CR43","first-page":"3959","volume":"17","author":"G Bahari","year":"2016","unstructured":"Bahari G, Hashemi M, Naderi M, Taheri M (2016) TET2 promoter DNA methylation and expression in childhood acute lymphoblastic leukemia. Asian Pac J Cancer Prev 17(8):3959\u20133962","journal-title":"Asian Pac J Cancer Prev"},{"issue":"25","key":"1673_CR44","first-page":"6403","volume":"113","author":"AM Jankowska","year":"2009","unstructured":"Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J et al (2009) Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic\/myeloproliferative neoplasms. Blood J Am Soc Hematol 113(25):6403\u20136410","journal-title":"Blood J Am Soc Hematol"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-023-01673-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-023-01673-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-023-01673-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T14:35:31Z","timestamp":1706711731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-023-01673-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1673"],"URL":"https:\/\/doi.org\/10.1007\/s12288-023-01673-y","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]},"assertion":[{"value":"25 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were by the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Bioethics Committee of the Iran University of Medical Sciences. Informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}